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Reply 
To the Editor: 
We thank Dr. Raskin for his thoughtful and provoca- 
tive comments regarding computed tomography (CT) of the 
craniocervical junction in rheumatoid arthritis. We believe 
the difference between his work and ours, particularly 
regarding flexion and extension computed tomographic 
views, may be explained on the basis of patient selection. In 
Raskin’s work, C1’ scans were performed on all rheumatoid 
arthritis patients in whom there was atlantoaxial subluxa- 
tion. Other clinical features were apparently not a consider- 
ation in patient selection. 
In our study, patients were retrospectively reviewed 
because they were possible neurosurgery candidates, 
regardless of the presence or absence of anterior subluxa- 
tion. We also considered posterior subluxation, pseudo- 
basilar vagination, and other abnormalities in evaluating 
these patients. 
In any population such as this, in whom there are 
neurologic deficits to begin with, we elect not to perform 
flexion and extension views for several reasons. First, 
symptoms in these seriously ill patients might be exacerbat- 
ed by performance of flexion. Second, the patients are 
unable to flex fully due to their clinical status, and are unable 
to maintain a position of flexion. Third, different patients 
could maintain different degrees of flexion. 
Thus, we believe degree of flexion was not reproduc- 
ible from patient to patient. Indeed, there may not have been 
reproducibility between consecutive examination results in 
the same patient. Therefore, we elected to evaluate star)- 
dardized neutral examinations. Even on plain radiographs, 
the reproducibility of flexion in the lateral projection is an 
important consideration in the evaluation of flexion and 
extension radiographs. 
We concur with Dr. Raskin and his colleagues that 
computed tomography should not be a screening examina- 
tion, but it may be useful in selected cases. In our patient 
population, not only were we unable to standardize the 
positioning of the patients and flexion, but flexion itself may 
have been potentially hazardous. 
Ethan M. Braunstein, MD 
University of Michigan Medical School 
University Hospitals 
Ann Arbor, MI 
Connective tissue disease after augmentation 
mammoplasty 
TO the Editor: 
We read with great interest the report by Kurnagai et 
al on 18 patients who developed connective tissue disease 
after cosmetic surgery (1). We have reported 3 patients in 
Singapore who developed connective tissue disease after 
augmentation mammoplasty (2). One patient had features of 
systemic lupus erythematosus. Another had features of 
progressive systemic sclerosis. Unlike the patients described 
by Kumagai, this patient responded to steroids and not to 
nonsteroidal antiinflammatory drugs. The third patient had 
features of idiopathic thrombocytopenic purpura. Steroids 
and cytotoxic agents were used without success, and sple- 
nectomy was performed but yielded no improvement. Since 
there was no report of this clinical manifestation in Kuma- 
gai’s large series of patients, this may represent a new 
clinical finding. 
In the course of our review of the literature on 
“human adjuvant disease,” we noted 2 reports which sug- 
gest that there may be an acute form of the condition as well. 
Uretsky et al (3) in 1979 described a patient who developed 
arthritis, renal failure, and bilateral pulmonary infiltrates 
shortly after bilateral silicone transplant. Chastre et al(4) in 
1983 described 3 patients in France who developed acute 
pneumonitis 1-3 days after subcutaneous injection of sili- 
cone. The patients developed acute respiratory failure. 
Known infective agents were excluded as the cause. Silicone 
was found in the cells and supernatant from bronchoalveolar 
lavage. These observations would suggest that silicone could 
cause an acute disease in humans. 
Although a causal relationship between the cosmetic 
surgery and subsequent development of connective tissue 
disease in humans is difficult to prove, a study involving 
male transsexual patients who have undergone sex change 
operation and received silicone implants or injections may 
shed some light on this difficult issue. We propose to study 
the problem in such patients in Singapore, with particular 
emphasis on the material injected and possible host factors. 
We regret the omission of HLA typing results in Kumagai’s 
18 patients and the 28 others they reviewed from the 
Japanese literature. 
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